Published : 2021-06-09

CLINICAL APPLICATIONS OF PACLITAXEL IN CANCER THERAPY

Kinga Byk

Filip Charuk

Ewa Olędzka

Marcin Sobczak

Monika Zielińska-Pisklak

Abstract

Paclitaxel (PTX) is a natural anti-cancer drug – a terpene alkaloid from the taxane group, used in the treatment of non-small cell lung carcinoma, ovarian and breast cancer as well Kaposi’s sarcoma. PTX shows a very good therapeutic effect when is used in monotherapy and in combination with other anti-cancer drugs. For the first time, it was isolated from the Pacific yew bark (Taxus brevifolia) and introduced into treatment under the name “Taxol” by the American biopharmaceutical company Bristol-Myers Squibb. The basic mechanism of its action consists in blocking the cell cycle during the G2/M phase by blocking depolymerization of microtubules, which inhibits mitosis. Moreover, PTX can cause cell necrosis through multipolar divisions and incorrect chromosome segregation.

Keywords:

paclitaxel, breast cancer, non-small cell lung cancer, immunotherapy, nab-paclitaxel


Most read articles by the same author(s)


Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Byk, K., Charuk, F., Olędzka, E., Sobczak, M., & Zielińska-Pisklak, M. (2021). CLINICAL APPLICATIONS OF PACLITAXEL IN CANCER THERAPY. Prospects in Pharmaceutical Sciences, 19(2), 9–17. https://doi.org/10.56782/pps.10

Altmetric indicators


Cited by / Share


Licence


Editorial Team
Stefana Banacha 1
02-097 Warsaw, Poland
biuletynfarmacji@wum.edu.pl
Publisher:
Foundation for Students and Graduates of the Medical University of Warsaw "Koło Medyków"
ul. Wojciecha Oczki 1a,
02-007 Warszawa,
tel. 22 628 83 06
About:
Copyright 2021 by
OJS Support and Customization by LIBCOM
Platform & workfow by OJS/PKP